|
NEWS
HERA Trial: Invasive Lobular Breast Carcinoma Patients Derived Same Benefit From Trastuzumab Maintenance
May 7, 2013 PIK3CA Mutations Negatively Affect Survival in Trastuzumab-Treated HER2-Positive Breast Cancer
May 6, 2013
CONNECT WITH US
|
|
||||||||||||||||
Recently published research questions the need for the advised restriction against the use of soyfoods by women with a history of breast cancer.
Accelerated partial-breast irradiation is a shorter, alternative radiation technique for select patients with favorable early-stage breast cancer. We review here the different modalities of delivery and discuss the possible benefits and harms associated with these treatments.
Additional insight into the biology of ER-positive breast cancers, particularly the higher risk luminal B cancers, could aid in identifying potential targets and new, effective therapies. And though the majority of triple-negative breast cancers are the “basal-like” subtype, significant proportions are in other subtypes.
A 22-year-old female collegiate soccer player complains of a painful palpable area in her right breast accompanied by a straw-colored nipple discharge. Because she is extremely anxious and has had previous excisional biopsies, you decide to perform a lumpectomy.
A 38-year-old female (para 3, gravida 3), complains of persistent bilateral mammary gland pain associated with a “lumpy” feeling when she does a self-examination. She carries a family history of breast cancer in both her mother and older sister.
A 71-year-old woman was receiving a multi-agent chemotherapeutic regimen following a lumpectomy for breast cancer. After the second round of treatment, she presented for medical care due to persistent, intensely painful ulceration of the contralateral breast.
A 31-year-old woman has undergone a lumpectomy for a small, estrogen receptor–positive breast tumor. She acutely develops a painful, hot fluctuant lump on her chin. What would be the most appropriate thing to do first?
As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conference.
This year's coverage of ASH 2012 includes write-ups of the most important information to come out of this year's event.
Cancer Network presents exclusive coverage from SABCS 2012, featuring the top stories to come out of this year's meeting.
This year's coverage of the European Society for Medical Oncology (ESMO) 2012 Congress includes write-ups of the most important information to come out of this year's event.
Cancer Network presents exclusive coverage from the 2012 ASCO Breast Cancer Symposium, featuring the top stories to come out of this year's meeting.Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy